Drug Profile
Research programme: mood disorder and neurological disorder therapeutics - Phenoquest
Alternative Names: AF-08 mAb; AFC-08Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Affectis Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Dinoprostone receptor antagonists; Purinergic P2 receptor antagonists; TMEFF2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in Germany
- 22 Oct 2015 Preclinical development is ongoing in Germany
- 22 Oct 2015 AFC 08 licensed to Phenoquest (Affectis' pipeline, October 2015)